Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results , but sales fell by 1.6% year on year to $15.53 ...

MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo ...

(RTTNews) - Merck (MRK), known as MSD outside of the United States and Canada, Monday announced the first presentation of results from the Phase 3 Zenith trial evaluating Winrevair (sotatercept ...

The first-in-class activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, given the trade name Winrevair, has been cleared to improve exercise capacity, improve lung function, and reduce the ...

New product launches like WINREVAIR are exceeding expectations and offsetting pipeline risk. Merck trades at a steep P/E discount despite strong fundamentals and clear growth visibility.

CEO Rob Davis highlighted the progress in commercialized medicines and vaccines, emphasizing the strength of newer product launches such as WINREVAIR and CAPVAXIVE. Revenue for Q1 2025 reached $15 ...

Winrevair, the company’s recently launched treatment for a rare lung disease, beat analyst expectations with $280 million in revenue. The drugmaker is still dealing with the fallout over its HPV ...

Sales Grew 6% WINREVAIR Sales Were $280 Million Animal Health Sales Grew 5% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 10% GARDASIL/GARDASIL 9 Sales Declined 41% to $1.3 ...

Indeed, Merck was the best Dow Jones stock today, jumping 5% to a record-high close of $131.75 after the Food and Drug Administration (FDA) approved Winrevair, the company's treatment for ...

WINREVAIR showed a reduction in the composite endpoint of all-cause death, lung transplantation, and PAH worsening-related hospitalization by 76% (HR=0.24 [95% CI, 0.13-0.43]; p The ZENITH study ...